Effects of Estrogen Receptor Expression and Histopathology on Annual Hazard Rates of Death from Breast Cancer
- 10 May 2006
- journal article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 100 (1), 121-126
- https://doi.org/10.1007/s10549-006-9231-y
Abstract
Breast cancer incidence rates vary according to estrogen receptor expression (ER) and histopathology. We hypothesized that annual mortality rates from breast cancer after initial diagnosis (hazard rates) might also vary by ER and histopathology. We accessioned the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER, 1992–2002) program to estimate hazard rates according to ER (positive and negative) and histopathology (duct, tubular, lobular, medullary, inflammatory, papillary, and mucinous types). We used spline functions to model hazard rates free of strongly parametric assumptions for ER negative and positive cases overall and by histopathology. Hazard rates for ER negative and ER positive cases were distinct and non-proportional. At 17 months, ER negative hazard rates peaked at 7.5% per year (95% CI, 7.3–7.8% per year) then declined, whereas ER positive hazard rates lacked a sharp early peak and were comparatively constant at 1.5–2% per year. Falling ER negative and constant ER positive hazard rates crossed at 7 years; after which, prognosis was better for ER negative cases. Among ER positive and negative cases, there were proportional and non-proportional hazards according to histopathologic type, but the two basic ER-associated patterns were maintained. Hazard rates differed quantitatively and qualitatively according to ER and histopathology. These large-scale population-based results seem consistent with genomic studies, demonstrating two main classes of breast cancers with distinct prognoses according to ER expression.Keywords
This publication has 24 references indexed in Scilit:
- The time-related changes of the importance of prognostic factors in breast cancer. A sequential multivariate analysis of 1423 Japanese patientsBreast Cancer Research and Treatment, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Does surgery unfavourably perturb the “natural history” of early breast cancer by accelerating the appearance of distant metastases?European Journal Of Cancer, 2005
- Distinct breast cancer incidence and prognostic patterns in the NCI?s SEER program: suggesting a possible link between etiology and outcomeBreast Cancer Research and Treatment, 2005
- Hazard rates of recurrence following diagnosis of primary breast cancerBreast Cancer Research and Treatment, 2005
- Is Male Breast Cancer Similar or Different than Female Breast Cancer?Breast Cancer Research and Treatment, 2004
- Recent Trends in U.S. Breast Cancer Incidence, Survival, and Mortality RatesJNCI Journal of the National Cancer Institute, 1996
- Flexible Methods for Analyzing Survival Data Using Splines, with Applications to Breast Cancer PrognosisJournal of the American Statistical Association, 1992
- LONG-TERM SURVIVAL OF WOMEN WITH BREAST CANCERThe Lancet, 1984
- Regression Models and Non-Proportional Hazards in the Analysis of Breast Cancer SurvivalJournal of the Royal Statistical Society Series C: Applied Statistics, 1984